Table 1.
Co-amplification of ERBB2 and CCNE1 across tumor types in the cancer genome atlas.
| ERBB2 AMP | CCNE1 AMP | Co-AMP | Total | ||
|---|---|---|---|---|---|
| Tumor type | N | N | N | % | N |
| Breast invasive carcinoma | 169 | 76 | 18 | 10.70% | 1,099 |
| Stomach adenocarcinoma | 100 | 67 | 37 | 37.00% | 440 |
| Uterine corpus endometrioid carcinoma | 63 | 73 | 27 | 42.90% | 547 |
| Ovarian serous cystadenocarcinoma | 56 | 203 | 23 | 41.10% | 595 |
| Bladder urothelial carcinoma | 47 | 52 | 10 | 21.30% | 414 |
| Esophageal carcinoma | 42 | 21 | 9 | 21.40% | 184 |
| Lung squamous cell carcinoma | 38 | 90 | 10 | 26.30% | 524 |
| Lung adenocarcinoma | 36 | 68 | 6 | 16.70% | 553 |
| Colon adenocarcinoma | 36 | 11 | 3 | 8.30% | 504 |
| Cervical and endocervical cancer | 23 | 13 | 3 | 13.00% | 295 |
| Head and neck squamous cell carcinoma | 19 | 13 | 2 | 10.50% | 524 |
| Pancreatic adenocarcinoma | 17 | 12 | 2 | 11.80% | 184 |
| Uterine carcinosarcoma | 15 | 25 | 5 | 33.30% | 56 |
| Rectum adenocarcinoma | 14 | 1 | 0 | 0.00% | 169 |
| Sarcoma | 11 | 50 | 4 | 36.40% | 263 |
| Liver hepatocellular carcinoma | 6 | 18 | 1 | 16.70% | 376 |
| Prostate adenocarcinoma | 4 | 3 | 0 | 0.00% | 499 |
| Kidney papillary cell carcinoma | 3 | 0 | 0 | 0.00% | 303 |
| Glioblastoma multiforme | 1 | 11 | 0 | 0.00% | 607 |
| Brain lower grade glioma | 1 | 4 | 0 | 0.00% | 515 |
| Testicular germ cell tumor | 1 | 2 | 0 | 0.00% | 150 |
| Skin cutaneous melanoma | 1 | 3 | 0 | 0.00% | 104 |
| Adrenocortical cancer | 1 | 7 | 1 | 100.00% | 90 |
| Diffuse large B-cell lymphoma | 1 | 0 | 0 | 0.00% | 48 |
| Cholangiocarcinoma | 1 | 0 | 0 | 0.00% | 36 |
| Total | 706 | 823 | 161 | 22.80% | 9,079 |